Peptonic Medical provides further clarification regarding the acquisition of the strategic shareholding in DGH International AB (formerly Intellego Technologies AB)
Peptonic Medical AB (publ) ("Peptonic" or the "Company") provides clarifying information in connection with the press release published on 2 September 2026 regarding the Company’s acquisition of the shareholding in DGH International AB ("DGH"). The press release stated that Mangold Fondkommission AB was one of the sellers – Mangold solely brokered the sale of the shares.
The press release stated that Mangold Fondkommission AB was one of the sellers of the shares – this information is now corrected to clarify that Mangold Fondkommission AB solely brokered the sale of the shares.
For further information, please contact
Daniel Rudeklint
Interim CEO, Peptonic Medical AB
Email: daniel.rudeklint@peptonicmedical.se
Phone: +46 73 158 02 73
About Peptonic Medical AB
Peptonic Medical AB (publ) is a Swedish medical technology company that develops and sells clinically proven self-care products in intimate women’s health. Under the VagiVital and Vernivia brands, the Company offers an over-the-counter portfolio of effective and gentle products that help women understand, treat and prevent common medical conditions affecting intimate health. Peptonic’s growth strategy is based on geographic expansion, particularly in the US and Europe, and on continuously strengthening its product portfolio through in-house product development and strategic acquisitions.
The Company is headquartered in Stockholm, Sweden, and has the subsidiaries Peptonic Medical Inc. and Common Sense Marketing Inc. in the US. Peptonic Medical was founded in 2009 and has been listed on Spotlight Stock Market since 2014.